Boehringer Ingelheim
BI 765423
Idiopathic Pulmonary Fibrosis
Countdown
247days
Phase 2 readout · Mar 11, 2027
What's at stake
Phase 2 trial results for BI 765423 in Idiopathic Pulmonary Fibrosis are due Mar 11, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07036523: Phase 2 trial, sponsor Boehringer Ingelheim, drug BI 765423. Primary completion date 2027-03-11 (estimated).”